Airija - anglų - HPRA (Health Products Regulatory Authority)

ltt pharma limited - budesonide, formoterol fumarate dihydrate - powder for inhalation - 200/6 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics and other drugs for obstructive airway diseases - it is indicated in adults and adolescents aged 12 to 17 years for the regular treatment of asthma and for the symptomatic treatment of patients with severe copd

Airija - anglų - HPRA (Health Products Regulatory Authority)

ltt pharma limited - budesonide, formoterol fumarate dihydrate - powder for inhalation - 400/12 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics and other drugs for obstructive airway diseases - it is indicated in adults and adolescents aged 12 to17 years for the regular treatment of asthma and for the symptomatic treatment of patients with severe copd

Airija - anglų - HPRA (Health Products Regulatory Authority)

orion corporation - budesonide; formoterol fumarate dihydrate - inhalation powder - 80/4.5 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Airija - anglų - HPRA (Health Products Regulatory Authority)

rowex ltd - budesonide; formoterol fumarate dihydrate - inhalation powder, pre-dispensed - 160 microg/4.5 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Airija - anglų - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - budesonide dihydrate; formoterol fumarate dihydrate - inhalation powder - 200/6 µg/µg - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Airija - anglų - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - budesonide dihydrate; formoterol fumarate dihydrate - inhalation powder - 400/12 µg/µg - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Jordanija - anglų - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - budesonide 160 mcg/dose, formoterol fumarate dihydrate 4.5 mcg/dose - 160 mcg/dose, dihydrate 4.5 mcg/dose

Jordanija - anglų - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - budesonide 160 mcg/dose, formoterol fumarate dihydrate 4.5 mcg/dose - 160 mcg/dose, dihydrate 4.5 mcg/dose

Kanada - anglų - Health Canada

astrazeneca canada inc - budesonide; glycopyrronium (glycopyrronium bromide); formoterol fumarate dihydrate - aerosol, metered dose - 160mcg; 7.2mcg; 5mcg - budesonide 160mcg; glycopyrronium (glycopyrronium bromide) 7.2mcg; formoterol fumarate dihydrate 5mcg - antimuscarinics antispasmodics

Izraelis - anglų - Ministry of Health

abic marketing ltd, israel - budesonide micronized; formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 9 mcg/dose; budesonide micronized 320 mcg/dose - formoterol and budesonide - duoresp spiromax 320/9 mcg/dose is indicated in adults and adolescents, age 12 -17 for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting β2 adrenoceptor-agonist) is appropriate:-patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting β2 adrenoceptor-agonists.or- patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptoragonists.chronic obstructive pulmonary disease (copd)duoresp spiromax 320/9 mcg/dose is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in i second (fev1) < 70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy